Hans-Stefan Hofmann1,2, Jan Braess3, Susanne Leipelt3, Michael Allgäuer4, Monika Klinkhammer-Schalke5, Tamas Szoeke1, Christian Grosser1, Michael Pfeifer6, Michael Ried2. 1. Department of Thoracic Surgery, Hospital Barmherzige Brüder Regensburg, Prüfeninger Straße 86, 93049 Regensburg, Germany. 2. Department of Thoracic Surgery, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. 3. Department of Oncology and Hematology, Hospital Barmherzige Brüder Regensburg, Prüfeninger Straße 86, 93049 Regensburg, Germany. 4. Department of Radiotherapy, Hospital Barmherzige Brüder Regensburg, Prüfeninger Straße 86, 93049 Regensburg, Germany. 5. Tumour Centre Regensburg, University Regensburg, Am BioPark 9, 93053 Regensburg, Germany. 6. Department of Pneumology, Hospital Barmherzige Brüder Regensburg, Prüfeninger Straße 86, 93049 Regensburg, Germany.
Abstract
BACKGROUND: Non-small cell lung cancer (NSCLC) with mediastinal lymph node involvement (N2) is a heterogeneous entity. The objective of this analysis is to investigate the results of treatment strategies for N2-positive patients. METHODS: Retrospective study (2009-2014) of 104 consecutive patients with stage IIIA-N2 NSCLC classified according to the Robinson classification (IIIA1-IIIA4) and treated within a multimodality treatment regime. RESULTS: The Robinson subgroups were: IIIA1 (n=27), IIIA3 (n=60) and IIIA4 (n=17). We had no stage IIIA2 samples because we did not perform an intraoperative frozen section of lymph nodes. Surgical resection with systematic lymph node dissection was performed in all patients with stage IIIA1 (n=27). After chemotherapy or chemo-/radiotherapy, 53.3% of patients in stage IIIA3 (n=32) and 11.7% of patients in stage IIIA4 (n=2) underwent surgery with curative intention. R0 was achieved in 92.6% in stage IIIA1, 93.8% in stage IIIA3 and 100% in stage IIIA4. The 30-day mortality was 3.2%. The overall median survival was 31.7 months (5-year survival was 30.5%). There were no significant differences (P=0.583) in survival regarding the Robinson subgroups. Patients who underwent tumour resection had significantly better median survival (39.8 vs. 19.6 months; P=0.014) compared to patients treated conservatively. Deviation from the interdisciplinary recommended therapy (12%) led to a reduced median survival (11.4 vs. 31.8 months; P=0.137). CONCLUSIONS: N2-patients should be subclassified according to the Robinson classification and discussed in the tumour board. Surgical resection should be recommended in specific cases of N2-disease (non-bulky, sensitivity to systemic treatment).
BACKGROUND: Non-small cell lung cancer (NSCLC) with mediastinal lymph node involvement (N2) is a heterogeneous entity. The objective of this analysis is to investigate the results of treatment strategies for N2-positive patients. METHODS: Retrospective study (2009-2014) of 104 consecutive patients with stage IIIA-N2 NSCLC classified according to the Robinson classification (IIIA1-IIIA4) and treated within a multimodality treatment regime. RESULTS: The Robinson subgroups were: IIIA1 (n=27), IIIA3 (n=60) and IIIA4 (n=17). We had no stage IIIA2 samples because we did not perform an intraoperative frozen section of lymph nodes. Surgical resection with systematic lymph node dissection was performed in all patients with stage IIIA1 (n=27). After chemotherapy or chemo-/radiotherapy, 53.3% of patients in stage IIIA3 (n=32) and 11.7% of patients in stage IIIA4 (n=2) underwent surgery with curative intention. R0 was achieved in 92.6% in stage IIIA1, 93.8% in stage IIIA3 and 100% in stage IIIA4. The 30-day mortality was 3.2%. The overall median survival was 31.7 months (5-year survival was 30.5%). There were no significant differences (P=0.583) in survival regarding the Robinson subgroups. Patients who underwent tumour resection had significantly better median survival (39.8 vs. 19.6 months; P=0.014) compared to patients treated conservatively. Deviation from the interdisciplinary recommended therapy (12%) led to a reduced median survival (11.4 vs. 31.8 months; P=0.137). CONCLUSIONS: N2-patients should be subclassified according to the Robinson classification and discussed in the tumour board. Surgical resection should be recommended in specific cases of N2-disease (non-bulky, sensitivity to systemic treatment).
Authors: Nirmal K Veeramachaneni; Richard H Feins; Briana J K Stephenson; Lloyd J Edwards; Felix G Fernandez Journal: Ann Thorac Surg Date: 2012-06-27 Impact factor: 4.330
Authors: Chi-Fu Jeffrey Yang; Arvind Kumar; Brian C Gulack; Michael S Mulvihill; Matthew G Hartwig; Xiaofei Wang; Thomas A D'Amico; Mark F Berry Journal: J Thorac Cardiovasc Surg Date: 2015-12-21 Impact factor: 5.209
Authors: Yi-Chen Yeh; Kyuichi Kadota; Jun-ichi Nitadori; Camelia S Sima; Nabil P Rizk; David R Jones; William D Travis; Prasad S Adusumilli Journal: Eur J Cardiothorac Surg Date: 2015-09-15 Impact factor: 4.191
Authors: David Gilligan; Marianne Nicolson; Ian Smith; Harry Groen; Otilia Dalesio; Peter Goldstraw; Matthew Hatton; Penelope Hopwood; Christian Manegold; Franz Schramel; Hans Smit; Jan van Meerbeeck; Matthew Nankivell; Mahesh Parmar; Cheryl Pugh; Richard Stephens Journal: Lancet Date: 2007-06-09 Impact factor: 79.321